VELETRI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8598227 | ACTELION | Epoprostenol formulation and method of making thereof |
Feb, 2027
(3 years from now) | |
| US8318802 | ACTELION | Epoprostenol formulation and method of making thereof |
Mar, 2027
(3 years from now) | |
Veletri is owned by Actelion.
Veletri contains Epoprostenol Sodium.
Veletri has a total of 2 drug patents out of which 0 drug patents have expired.
Veletri was authorised for market use on 27 June, 2008.
Veletri is available in injectable;injection dosage forms.
The generics of Veletri are possible to be released after 15 March, 2027.
Drugs and Companies using EPOPROSTENOL SODIUM ingredient
Market Authorisation Date: 27 June, 2008
Treatment: NA
Dosage: INJECTABLE;INJECTION
How can I launch a generic of VELETRI before it's drug patent expiration?
More Information on Dosage
VELETRI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic